Abstract Library

#4657 Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,

#4176 A single center experience of locoregional treatments application in neuroendocrine liver metastases

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are complicate with neuroendocrine hepatic metastasis (NELM) in approximately 60% of cases. Loco-regional interventional radiology procedures are widely approved in treatment of hepatocellular carcinoma (HCC) and in last years found more and more application in liver metastasis.

Conference:

Presenting Author: Ferretti S

Authors: Masoni B, Ferretti S, Rossi R, Ceriani R, Laffi A,

Keywords: neuroendocrine, loco regional treatment, liver metastasis, interventional radiology, embolization, ablation,

#4091 Grade 2 (G2) gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs): Risk stratification beyond Ki-67?

Introduction: G2 GEP-NETs are well-differentiated neuroendocrine neoplasms with Ki-67 proliferation index of 3-20%. Rather than behaving as a monolithic category, these neoplasms are often characterized by an unpredictable outcome, and additional biomarkers are needed.

Conference:

Presenting Author:

Authors: Laffi A, Zerbi A, Lavezzi E, Carrara S, Rossi E,

Keywords: GEP NET, G2, neuroendocrine tumor, neuroendocrine,

#3821 Risk of venous thromboembolism in pancreatic neuroendocrine neoplasms

Introduction: Venous thromboembolism (VTE) is a leading cause of morbidity and death in cancer. The incidence of VTE is increased in different cancers such as pancreatic ductal adenocarcinoma, however limited evidence is present this risk for pancreatic neuroendocrine neoplasms (pan-NENs).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Laffi A, Cella C, Rubino M, Spada F,

Keywords: Venous thromboembolism, pancreatic neuroendocrine tumor, pancreatic neuroendocrine carcinoma, NEN, VTE,

#3635 Non-responders to Peptide Receptor Radionuclide Therapy (PRRT) – A single center retrospective analysis

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has become the standard of care for patients (pts) with positive somatostatin receptor image, grade (G)1/2 gastrointestinal (GI) neuroendocrine tumors (NETs) after Somatostatin Analogues (SSAs) failure.

Conference:

Presenting Author: Laffi A

Authors: Laffi A, Rodari M, Lania A, Zerbi A, Elisabetta L,

Keywords: PRRT, neuroendocrine tumor, NET, Nuclear Medicine,